BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Brenzavvy (Bexagliflozin) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Brenzavvy (Bexagliflozin)\, from Clinical
 Trials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05612594-8714@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Brenzavvy (Bexagliflozin): Phase 4 readout est. (NCT05612594)
DESCRIPTION:Brenzavvy (Bexagliflozin)\, phase 4.\nStudy: Adipose Dysfunctio
 n\, Imaging\, Physiology\, and Outcomes With Sodium Glucose Cotransporter 
 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA Study\nEstimated primary
  completion: September 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/bexagliflozin#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05612594
URL:https://assetmemo.bio/drug/bexagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06600178-8714@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Brenzavvy (Bexagliflozin): Phase 1 readout est. (NCT06600178)
DESCRIPTION:Brenzavvy (Bexagliflozin)\, phase 1.\nStudy: Study Targeting My
 ocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRO
 NG)\nEstimated primary completion: 31 October 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/bexagliflozin#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06600178
URL:https://assetmemo.bio/drug/bexagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07547878-8714@assetmemo.bio
DTSTAMP:20261121T005657Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Brenzavvy (Bexagliflozin): Phase 4 readout est. (NCT07547878)
DESCRIPTION:Brenzavvy (Bexagliflozin)\, phase 4\, Type 2 Diabetes.\nStudy: 
 Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies
  (RAPID-CKD)\nEstimated primary completion: 31 March 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/bexagliflozin#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07547878
URL:https://assetmemo.bio/drug/bexagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
